Graham D, Harding M, Nielsen D
Methods Mol Biol. 2022; 2547:437-490.
PMID: 36068473
DOI: 10.1007/978-1-0716-2573-6_16.
Talal A, Ding Y, Venuto C, Chakan L, McLeod A, Dharia A
PLoS One. 2020; 15(4):e0231467.
PMID: 32302325
PMC: 7164646.
DOI: 10.1371/journal.pone.0231467.
Li W, Wang Z, Liu Z
Environ Health Prev Med. 2016; 21(6):480-486.
PMID: 27699691
PMC: 5112199.
DOI: 10.1007/s12199-016-0570-y.
Gutwinski S, Schoofs N, Stuke H, Riemer T, Wiers C, Bermpohl F
Harm Reduct J. 2016; 13:7.
PMID: 26879120
PMC: 4754801.
DOI: 10.1186/s12954-016-0095-0.
Mitchell S, Gryczynski J, Kelly S, OGrady K, Jaffe J, Olsen Y
J Drug Issues. 2014; 44(1):69-82.
PMID: 25364037
PMC: 4214068.
DOI: 10.1177/0022042613491106.
Management of opioid addiction with buprenorphine: French history and current management.
Polomeni P, Schwan R
Int J Gen Med. 2014; 7:143-8.
PMID: 24623988
PMC: 3949694.
DOI: 10.2147/IJGM.S53170.
Proopiomelanocortin (POMC) expression and conditioned place aversion during protracted withdrawal from chronic intermittent escalating-dose heroin in POMC-EGFP promoter transgenic mice.
Niikura K, Zhou Y, Ho A, Kreek M
Neuroscience. 2013; 236:220-32.
PMID: 23337531
PMC: 3596435.
DOI: 10.1016/j.neuroscience.2012.12.071.
Medication assisted treatment in US drug courts: results from a nationwide survey of availability, barriers and attitudes.
Matusow H, Dickman S, Rich J, Fong C, Dumont D, Hardin C
J Subst Abuse Treat. 2012; 44(5):473-80.
PMID: 23217610
PMC: 3602216.
DOI: 10.1016/j.jsat.2012.10.004.
Changes in somatic disease incidents during opioid maintenance treatment: results from a Norwegian cohort study.
Skeie I, Brekke M, Gossop M, Lindbaek M, Reinertsen E, Thoresen M
BMJ Open. 2011; 1(1):e000130.
PMID: 22021771
PMC: 3191421.
DOI: 10.1136/bmjopen-2011-000130.
Measuring the incentive value of escalating doses of heroin in heroin-dependent Fischer rats during acute spontaneous withdrawal.
Seip K, Reed B, Ho A, Kreek M
Psychopharmacology (Berl). 2011; 219(1):59-72.
PMID: 21748254
PMC: 3249530.
DOI: 10.1007/s00213-011-2380-7.
Addiction and brain reward and antireward pathways.
Gardner E
Adv Psychosom Med. 2011; 30:22-60.
PMID: 21508625
PMC: 4549070.
DOI: 10.1159/000324065.
Human behavioral pharmacology, past, present, and future: symposium presented at the 50th annual meeting of the Behavioral Pharmacology Society.
Comer S, Bickel W, Yi R, de Wit H, Higgins S, Wenger G
Behav Pharmacol. 2010; 21(4):251-77.
PMID: 20664330
PMC: 2913311.
DOI: 10.1097/FBP.0b013e32833bb9f8.
Pharmacotherapy in the treatment of addiction: methadone.
Kreek M, Borg L, Ducat E, Ray B
J Addict Dis. 2010; 29(2):200-16.
PMID: 20407977
PMC: 2885886.
DOI: 10.1080/10550881003684798.
The acquired Brugada syndrome and the paradox of choice.
Viskin S, Rosso R, Marquez M, Antzelevitch C
Heart Rhythm. 2009; 6(9):1342-4.
PMID: 19716090
PMC: 2754213.
DOI: 10.1016/j.hrthm.2009.07.033.
Pharmacologic treatments for opioid dependence: detoxification and maintenance options.
Kleber H
Dialogues Clin Neurosci. 2008; 9(4):455-70.
PMID: 18286804
PMC: 3202507.
Opioid receptors: some perspectives from early studies of their role in normal physiology, stress responsivity, and in specific addictive diseases.
Kreek M
Neurochem Res. 1996; 21(11):1469-88.
PMID: 8947936
DOI: 10.1007/BF02532387.
